Skip to content
ResearchBDX

BD (BDX) Q4 2026 Earnings: Margin Hits 28.6% as Alaris Weighs on FY2027

Editorial illustration for BD (BDX) Q4 2026 Earnings: Margin Hits 28.6% as Alaris Weighs on FY2027
Published Updated 5 min read

Summary

BD's fiscal Q4 2026 adjusted operating margin rose 2.8 points to 28.6% and adjusted EPS grew 27.3%, while the Alaris pump roll-off holds fiscal 2027 revenue growth to low single digits.

BD (BDX) fiscal Q4 2026 earnings showed a 2.8-point jump in adjusted operating margin and 27.3% growth in adjusted EPS, but the company's fiscal 2027 outlook points to a transition year shaped by the Alaris infusion-pump comparison. BD reported results for the quarter ended September 30, 2026 on November 5, 2026 through an 8-K press release and its earnings call [1][2].

Four questions framed this report: whether biologic drug-delivery devices could accelerate once the vaccine drag bottomed out, how fast Alaris replacement revenue would roll off, whether the largest consumables segment could sustain its acceleration, and how much of the EPS growth came from operations. Medical Essentials accelerated to 5.9%. BioPharma Systems grew 7.0%, although US growth slowed to 4.7%. The Alaris roll-off pushed Medication Management Solutions (MMS) into decline, and adjusted operating margin rose 2.8 percentage points [1][2]. For fiscal 2027, the company guides to low single-digit revenue growth and a roughly flat operating margin, with about half of EPS growth depending on a lower share count [2].

BD is one of the world's largest makers of medical consumables and devices and spun off its life sciences business in February 2026 [1]. It sells catheters, syringes and blood collection tubes to hospitals and labs, sells infusion pumps, medication dispensing cabinets and monitoring equipment to hospitals, and sells prefilled syringes to drug makers [3].

Margin expansion drove 27% EPS growth

BD's fourth-quarter adjusted EPS was $4.15, up 27.3% year over year and above the $4.03-$4.13 range implied by full-year guidance [1]. The CFO said adjusted gross margin was 56.8% and adjusted operating margin was 28.6%, up 1.8 and 2.8 percentage points, driven by productivity gains and favorable mix [2]. Adjusted operating margin in the prior-year quarter was 25.8% [4].

Operating profit, not buybacks, produced most of the EPS gain. Based on the disclosed margin, adjusted operating income was roughly $1.508 billion, up about 17%; diluted shares fell from 287 million to 274 million, which contributed only about 4.8 percentage points [1][2]. A $66 million tariff refund was excluded from adjusted results. Full-year adjusted operating margin was 25.0%, and most of the roughly 90 basis points of tariff impact was offset [1][2].

The fourth-quarter margin should not be extrapolated. BD guides fiscal 2027 adjusted operating margin to be roughly flat, including about 60 basis points of Alaris pressure, with adjusted EPS of $13.10-$13.30 and first-quarter adjusted EPS of $2.32-$2.37 [2]. Weighted shares are expected to fall to about 273 million, adding roughly 2.5 percentage points of EPS growth. Potential Section 232 tariff relief is not in the guidance, and the company gave no update on the El Paso warning letter this quarter [2].

Alaris roll-off turned MMS revenue negative

MMS revenue was $952 million in the fourth quarter, down 2.2% on a currency-neutral basis, after growing 2.3% in the third quarter [1][5]. US MMS revenue fell 5.6%. Management attributed the decline to strong Alaris replacement shipments in the prior-year quarter and said Alaris is still gaining share; the CEO said company growth excluding Alaris was about 7% this quarter [1][2].

Patient monitoring offset the gap. Advanced Patient Monitoring revenue was $317 million, up 17.3%, so the Connected Care segment still grew 2.1% [1]. BD guides the Alaris headwind to about 200 basis points in fiscal 2027 and about 250 basis points in the first quarter, and says it disappears in fiscal 2028. Because patient monitoring is switching IT systems, some shipments may move into the second quarter [2]. The roll-off steepened, but it remains within management's quantified framework.

Medical Essentials kept accelerating

Medical Essentials revenue was $1.786 billion in the fourth quarter, up 5.9% on a currency-neutral basis versus 3.2% in the third quarter [1][5]. US revenue grew 6.0%, and international revenue swung from a 3.2% decline in the third quarter to 5.8% growth. Specimen Management grew 9.4% and MDS grew 4.5% [1]. Management credited share gains, new capacity and more blood tubes collected per patient, and described China as stable [2].

The segment supplied about 37% of the company's revenue increase, confirming that US share gains continued [1]. Neither the contribution from competitor supply shortages nor the reason for the international rebound was disclosed, so the results do not show that China's volume-based procurement pressure has ended.

Conclusion

The quarter strengthens the case for BD's growth and profit conversion, and cash generation improved sharply. Fiscal 2026 free cash flow was $2.933 billion, up 42.5%, and the company repurchased about $2.4 billion of stock and repaid $2.4 billion of debt during the year [1][2]. Durability is limited by fiscal 2027 transition factors: the Alaris headwind is heaviest in the first quarter, and the fourth-quarter margin was partly a seasonal high [2]. The next report will show whether growth excluding Alaris holds at a mid-single-digit rate and whether first-quarter EPS lands within guidance.

Sources

[1] BDX 8-K filed 2026-11-05 · Q4 FY2026 earnings release (EX-99.1), 2026-11-05, BD 8-K press release, https://www.sec.gov/Archives/edgar/data/10795/000162828026070511/ex9919302026.htm

[2] BDX Q4 FY2026 earnings call 2026-11-05 · transcript, 2026-11-05, BD earnings call transcript, drillr://earning_call_summary/BDX/2026-11-05

[3] BDX 10-K filed 2025-11-25, 2025-11-25, BD 10-K, https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000010795

[4] BDX 8-K filed 2026-04-02 continuing-operations recast, 2026-04-02, BD 8-K, https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000010795

[5] BDX Q3 FY2026 8-K unit revenue, 2026-08-06, BD 8-K, https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000010795

Related:BDX

Want deeper analysis?

Ask drillr anything about BDX — powered by SEC filings, earnings calls, and real-time data.

Try drillr.ai for free

drillr can make mistakes. Information only — not investment advice. Learn more